Vioxx Shock Is Latest Headache For Rx Stocks; Is Election Day A Cure?
Executive Summary
Pfizer's $27 bil. devaluation during the third quarter is strong evidence that Wall Street's aversion to drug stocks goes far beyond the Vioxx withdrawal
You may also be interested in...
Antidepressant Safety Concerns Depress Zoloft; Forest, Wyeth Still Happy
Pfizer's Zoloft may feel the greatest negative performance impact from FDA's decision to require a class-wide black box warning for antidepressants
Antidepressant Safety Concerns Depress Zoloft; Forest, Wyeth Still Happy
Pfizer's Zoloft may feel the greatest negative performance impact from FDA's decision to require a class-wide black box warning for antidepressants
Merck Sees Slightly More Success With External Rx Than Internal Candidates
Merck has a slightly higher success rate with drug candidates developed through external licensing deals than with internally discovered compounds, Merck Senior Director-Strategic Research Initiatives, External Scientific Affairs Ronald Newbold said